EYPT - ピ―シビダ （EyePoint Pharmaceuticals Inc.） ピ―シビダEYPTのチャート
EYPTの企業情報
| symbol | EYPT |
|---|---|
| 会社名 | EyePoint Pharmaceuticals Inc （ピ―シビダ） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アイポイント・ファーマシューティカルズ(Eyepoint Pharmaceuticals Inc.)(旧名：pSivida Corp.)は主に慢性眼疾患の治療用の薬物送達製品を開発する。同社は目の裏目の病気の治療のための3つの製品を開発した。後部セグメントブドウ膜炎のためのMedidurは、主要な第III相臨床試験にあるリード製品候補である。糖尿病性黄斑浮腫（DME）のILUVIENは、米国および欧州連合（EU）諸国で販売されている主要ライセンス製品である。また、Retisertを含む。Medidurは、眼の後部に影響を与える慢性非感染性ブドウ膜炎（後部ブドウ膜炎）を治療するように設計される。ILUVIENは、単回注射からDMEの治療を提供する注射可能なマイクロインサートである。Retisertは、後区域ブドウ膜炎の治療を提供するインプラントである。同社の製品開発プログラムは、DurasertとTethadurの2つの技術プラットフォームを利用して、慢性疾患治療薬と生物製剤を提供することに重点を置く。 ピ―シビダは、米国の医薬品会社。目の奥の慢性疾患の治療に焦点を当てた医薬品「Durasert」と「Tethadur」を開発。また、製品候補「Medidur」は、第3相臨床試験段階である。同社の主要製品「ILUVIEN」は、欧州連合(EU)で承認され、米国食品医薬品局(FDA)では承認が保留されている。 |
| 本社所在地 | 480 Pleasant Street Watertown MA 02472 USA |
| 代表者氏名 | Goran A. Ando ゴラン・アンドド |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-926-5000 |
| 設立年月日 | 31868 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 44人 |
| url | www.eyepointpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/eypt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -25.12600 |
| 終値（lastsale） | 3.28 |
| 時価総額（marketcap） | 244399517.44 |
| 時価総額 | 時価総額（百万ドル） 250.36050 |
| 売上高 | 売上高（百万ドル） 2.96100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 228.89350 |
| 当期純利益 | 当期純利益（百万ドル） -53.17100 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Eyepoint Pharmaceuticals Inc revenues decreased 61% to $3M. Net loss increased from $18.5M to $53.2M. Revenues reflect United States segment decrease of 62% to $2.9M. Higher net loss reflects Research and Development Expense increase of 12% to $14.9M (expense) General and administrative increase of 3% to $10.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.52 to -$1.15. |
EYPTのテクニカル分析
EYPTのニュース
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation 2020/12/18 12:00:00 GlobeNewswire
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Cut to Hold at Zacks Investment Research 2020/10/24 08:34:42 Dakota Financial News
Zacks Investment Research cut shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and […]
Investment Analysts’ Weekly Ratings Updates for Eyepoint Pharmaceuticals (EYPT) 2020/10/23 15:26:41 The Olympia Report
A number of firms have modified their ratings and price targets on shares of Eyepoint Pharmaceuticals (NASDAQ: EYPT) recently: 10/21/2020 – Eyepoint Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development […]
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to “Buy” at Zacks Investment Research 2020/10/23 06:18:45 Transcript Daily
Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. The firm currently has $0.50 price objective on the stock. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to […]
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Lowered by Zacks Investment Research 2020/10/23 01:18:42 Dispatch Tribunal
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders […]
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation 2020/12/18 12:00:00 GlobeNewswire
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Cut to Hold at Zacks Investment Research 2020/10/24 08:34:42 Dakota Financial News
Zacks Investment Research cut shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and […]
Investment Analysts’ Weekly Ratings Updates for Eyepoint Pharmaceuticals (EYPT) 2020/10/23 15:26:41 The Olympia Report
A number of firms have modified their ratings and price targets on shares of Eyepoint Pharmaceuticals (NASDAQ: EYPT) recently: 10/21/2020 – Eyepoint Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development […]
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to “Buy” at Zacks Investment Research 2020/10/23 06:18:45 Transcript Daily
Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. The firm currently has $0.50 price objective on the stock. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to […]
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Lowered by Zacks Investment Research 2020/10/23 01:18:42 Dispatch Tribunal
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders […]
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation 2020/12/18 12:00:00 GlobeNewswire
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Cut to Hold at Zacks Investment Research 2020/10/24 08:34:42 Dakota Financial News
Zacks Investment Research cut shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and […]
Investment Analysts’ Weekly Ratings Updates for Eyepoint Pharmaceuticals (EYPT) 2020/10/23 15:26:41 The Olympia Report
A number of firms have modified their ratings and price targets on shares of Eyepoint Pharmaceuticals (NASDAQ: EYPT) recently: 10/21/2020 – Eyepoint Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development […]
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to “Buy” at Zacks Investment Research 2020/10/23 06:18:45 Transcript Daily
Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. The firm currently has $0.50 price objective on the stock. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to […]
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Lowered by Zacks Investment Research 2020/10/23 01:18:42 Dispatch Tribunal
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders […]